MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Biogen Inc

Gesloten

SectorGezondheidszorg

130.65 -0.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

130

Max

132.92

Belangrijke statistieken

By Trading Economics

Inkomsten

-122M

267M

Verkoop

-15M

2.5B

K/W

Sectorgemiddelde

12.24

63.778

EPS

3.44

Winstmarge

10.865

Werknemers

7,605

EBITDA

-158M

536M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+46.54% upside

Dividenden

By Dow Jones

Volgende Winsten

23 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-982M

20B

Vorige openingsprijs

131.13

Vorige sluitingsprijs

130.65

Nieuwssentiment

By Acuity

47%

53%

173 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Biogen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 sep 2024, 11:00 UTC

Top Nieuws

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 mei 2024, 15:56 UTC

Winsten
Acquisities, Fusies, Overnames

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Peer Vergelijking

Prijswijziging

Biogen Inc Prognose

Koersdoel

By TipRanks

46.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 192.43 USD  46.54%

Hoogste 265 USD

Laagste 135 USD

Gebaseerd op 25 Wall Street-analisten die 12-maands prijsdoelen bieden voor Biogen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

25 ratings

13

Buy

12

Hold

0

Sell

Technische score

By Trading Central

N/A / 141.43Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

173 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.